Clinical Pharmacogenetics Implementation Consortium drug-gene pairs with evidence-based guidelines
| Drugs | Genes |
|---|---|
| Abacavira | HLA-B*57:01 |
| Allopurinol | HLA-B*58:01 |
| Amitriptylinea | CYP2C19, CYP2D6 |
| Atazanavir | UGT1A1 |
| Atomoxetinea | CYP2D6 |
| Azathioprinea | TPMT, NUDT15 |
| Capecitabinea | DPYD |
| Carbamazepinea | HLA-A*31:01, HLA-B*15:02 |
| Citaloprama | CYP2C19 |
| Clomipraminea | CYP2C19, CYP2D6 |
| Clopidogrela | CYP2C19 |
| Codeinea | CYP2D6 |
| Desipraminea | CYP2D6 |
| Doxepina | CP2C19, CYP2D6 |
| Efavirenz | CYP2B6 |
| Escitalopram | CYP2C19 |
| Fluorouracila | DPYD |
| Fluvoxamine | CYP2D6 |
| Imipraminea | CYP2C19, CYP2D6 |
| Ivacaftor | CFTR |
| Mercaptopurinea | TPMT, NUDT15 |
| Nortriptylinea | CYP2D6 |
| Ondansetron | CYP2D6 |
| Oxcarbazepinea | HLA-B*15:02 |
| Paroxetine | CYP2D6 |
| Peg-interferon alfa-2a | IFNL3 (IL28B) |
| Peg-interferon alfa-2b | IFNL3 (IL28B) |
| Phenytoina | CYP2C9, HLA-B*15:02 |
| Rasburicase | G6PD |
| Ribavirin | IFNL3 (IL28B) |
| Sertraline | CYP2C19 |
| Simvastatin | SLCO1B1 |
| Succinylcholine | RYR1, CACNA1S |
| Tacrolimus | CYP3A5 |
| Tamoxifen | CYP2D6 |
| Tegafur | DPYD |
| Thioguaninea | TPMT, NUDT15 |
| Trimipraminea | CYP2C19, CYP2D6 |
| Tropisetron | CYP2D6 |
| Volatile anesthetics | RYR1, CACNA1S |
| Voriconazole | CYP2C19 |
| Warfarina | CYP2C9, CYP4F2, VKORC1 |
↵a The drug also has US Food and Drug Administration-designated pharmacogenetic labeling as a boxed warning, a contraindication, a warning and precaution, or a dosing and administration recommendation.
From the Clinical Pharmacogenetics Implementation Consortium, https://cpicpgx.org/genes-drugs.